Acurx Pharmaceuticals Stock Gains Attention After Zacks Upgrade to Buy
Acurx Pharmaceuticals Stock Gains Attention After Zacks Upgrade to Buy
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has drawn fresh market attention after Zacks upgraded the stock to a Zacks Rank #2 (Buy). The upgrade reflects stronger optimism around the companyâs earnings outlook and analyst estimate revisions.
Why the Upgrade Matters
Zacksâ rating system places major weight on earnings estimate revisions. When analysts raise their expectations, it can signal improving confidence in a companyâs near-term prospects. For Acurx Pharmaceuticals, the move to Buy suggests that Wall Street sentiment has become more favorable.
The upgrade does not guarantee stock gains, but it may increase investor interest, especially because ACXP operates in the biotechnology sector, where clinical progress and funding updates can quickly affect valuation.
Company Background
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections. The companyâs pipeline targets serious Gram-positive bacterial threats, including C. difficile infection, MRSA, VRE, and other drug-resistant bacteria.
Ibezapolstat Remains the Key Focus
The companyâs lead drug candidate is ibezapolstat, an oral antibiotic being developed for acute C. difficile infection and recurrent C. difficile infection. Acurx has said ibezapolstat is preparing for advancement into international Phase 3 clinical trials.
In earlier Phase 2 results, Acurx reported a 96% clinical cure rate and 0% recurrence among patients cured of infection. The company believes this profile may support a broader treatment strategy for both first-time and recurrent CDI cases.
Recent Financial Snapshot
For the first quarter ended March 31, 2026, Acurx reported cash of about $9.3 million, compared with $7.6 million at the end of 2025. The company also reported a quarterly net loss of $1.7 million, or $0.62 per diluted share, improving from a loss of $2.1 million, or $2.15 per diluted share, in the prior-year quarter.
Patent and Pipeline Developments
Acurx also announced that the USPTO granted a new patent for its DNA polymerase IIIC inhibitors, covering composition of matter and method of use. The patent extends to December 2039, subject to possible extensions under U.S. patent rules.
This patent coverage may strengthen the companyâs intellectual property position as it continues to develop its antibiotic pipeline.
Investor Takeaway
The Zacks upgrade gives ACXP a stronger near-term market signal, but investors should still consider the risks. Acurx remains a clinical-stage biotechnology company, meaning future value depends heavily on trial execution, regulatory progress, financing, and eventual commercial potential.
Still, the combination of improving earnings expectations, an active clinical program, and renewed attention around ibezapolstat has made Acurx Pharmaceuticals a stock to watch in the small-cap biotech space.
Disclaimer: This article is for informational purposes only and is not financial advice.
#SlimScan #GrowthStocks #CANSLIM